肝硬化腹水治疗进展

doi:10.3969/j.issn.1672-5069.2014.04.003

Abstract

Ma Hong, Shi Yiwen. Optimal management of patients with liver cirrhosis and ascites[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(4): 344-348.

[1] Sangiovanni A,Prati GM,Fasani P,et al. The natural history of compensated cirrhosis due to hepatitis C virus:A 17-year cohort study of 214 patients. Hepatology,2006,43（6）:1303-1310.
[2] Peng CY,Chien RN,Liaw Y.F. Hepatitis B virus-related decompensated liver cirrhosis:Benefits of antiviral therapy. J Hepatol,2012,57（2）:442-450.
[3] Stanley MM,Ochi S,Lee KK,et al. Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites. Veterans administration cooperative study on treatment of alcoholic cirrhosis with ascites. N Engl J Med,1989,321（24）:1632-1638.
[4] Addolorato G,Leggio L,Ferrulli A,et al. Effectiveness and safety of Baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis:Randomised,double-blind controlled study. Lancet,2007,370（9603）:1915-1922.
[5] Mónica G,Baccaro ME,Torre A,et al. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis:A prospective study with time-dependent analysis. Am J Gastroenterol,2009,104（6）:1382-1389.
[6] Reynolds TB,Lieberman FL,Goodman AR. Advantages of treatment of ascites without sodium restriction and without complete removal of excess fluid. Gut,1978,19（6）:549-553.
[7] 顾锡炳,刘霞英,徐月琴. 不限钠饮食与限钠饮食对肝硬化患者肾血流量及腹水消退的影响. 中华消化杂志,2008,28（1）:61-62.
[8] Koretz RL,Avenell A,Lipman TO. Nutritional support for liver disease. Cochrane Database Syst Rev,2012,16（5）:CD008344.
[9] Sorrentino P,Castaldo G,Tarantino L,et al. Preservation of nutritional-status in patients with refractory ascites due to hepatic cirrhosis who are undergoing prepeated paracentesis. J Gastroenterol Hepatol,2012,27（4）:813-822.
[10] Santos J,Planas R,Pardo A,et al. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. J Hepatol,2003,39（2）:187-192.
[11] Angeli P,Fasolato S,Mazza E,et al. Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis:Results of an open randomised clinical trial. Gut, 2010,59（1）:98-104.
[12] Raza M,Qureshi U,Humayoun M,et al. Effect of intravenous mannitol in mobilization of resistant cirrhotic ascites. Eur J Gastroenterol Hepatol,2011,23（2）:184-188.
[13] Abecasis R, Guevara M,Miguez C,et al. Long-term efficacy of torsemide compared with frusemide in cirrhotic patients with ascites. Scand J Gastroenterol,2001,36（3）:309-313.
[14] Marelli A,Bodini P,Reggiani A,et al. Comparison between torasemide and furosemide in the treatment of ascites in cirrhotic patients. Minerva medica,1997,88（3）:109-115.
[15] Orman ES,Hayashi PH,Bataller R,et al. Paracentesis is associated with reduced mortality in patients hospitalized with cirrhosis and ascites. Clin Gastroenterol Hepatol,2014,12（3）: 496-503.
[16] Horie S,Nagai H,Yuuki T,et al. Effectiveness of recombinant human serum albumin in the treatment of ascites in liver cirrhosis:Evidence from animal model. Gen Pharmacol,1998, 31（5）:811-815.
[17] Nakamura T,Sata M,Suzuki K,et al. Open-labeled randomized controlled trial to compare diuretic therapy with recombinant human serum albumin and diuretic therapy for therapeutic treatment of ascites in patients with advanced liver cirrhosis: An exploratory trial. Hepatol Res,2014,44（5）:502-514.
[18] Kasahara A, Kita K,Tomita E,et al. Repeated administration of recombinant human serum albumin caused no serious allergic reactions in patients with liver cirrhosis:A multicenter clinical study. J Gastroenterol,2008,43（6）: 464-472.
[19] Guyader D,Patat A,Ellis-Grosse EJ,et al. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology,2002,36（5）:1197-1205.
[20] Dahl E,Gluud L,Kimer N,et al. Meta-analysis: The safety and efficacy of vaptans（tolvaptan,satavaptan and lixivaptan） in cirrhosis with ascites or hyponatraemia. Aliment Pharmacol Ther,2012,36（7）:619-626.
[21] Okita K,Sakaida I,Okada M,et al. A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy,safety,and dose-response of tolvaptan in patients with decompensated liver cirrhosis. J Gastroenterol,2010,45（9）:979-987.
[22] Okita K,Kawazoe S,Hasebe C,et al. Dose-finding trial of tolvaptan in liver cirrhosis patients with hepatic edema:A randomized,double-blind,placebo-controlled trial. Hepatol Res, 2014,44（1）:83-91.
[23] Sakaida I,Kawazoe S,Kajimura K,et al. Tolvaptan for improvement of hepatic edema:A phase 3,multicenter,randomized, double-blind,placebo-controlled trial. Hepatol Res,2014,44（1）:73-82.
[24] Watson H,Jepsen P,Wong F,et al. Satavaptan treatment for ascites in patients with cirrhosis:A meta-analysis of effect on hepatic encephalopathy development. Metab Brain Dis,2013, 28（2）:301-305.
[25] Krag A,Moller S,Henriksen J,et al. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology,2007,46（6）:1863-1871.
[26] Lata J,Marecek Z,Fejfar T,et al. The efficacy of terlipressin in comparison with albumin in the prevention of circulatory changes after the paracentesis of tense ascites-a randomized multicentric study. Hepatogastroenterology,2007,54（79）:1930.
[27] 李冬月,吴博,尹逊海,等. 特利加压素治疗失代偿期肝硬化疗效观察.实用肝脏病杂志,2012,15（1）:59-60.
[28] Yang YY,Lin HC,Lee WC,et al. One-week losartan administration increases sodium excretion in cirrhotic patients with and without ascites. J Gastroenterol,2002,37（3）:194-199.
[29] Sourianarayanane A,Barnes D,McCullough A. Beneficial effect of midodrine in hypotensive cirrhotic patients with refractory ascites. Gastroenterol Hepatol （NY）,2011,7（2）:132-134.
[30] Minakari M,Faiiaz L,Rowshandel M,et al. Comparison of the effect of midodrine versus octreotide on hemodynamic status in cirrhotic patients with ascites. J Res Med Sci,2011,16（1）: 87-93.
[31] Kalambokis G,Fotopoulos A,Economou M,et al. Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites. J Hepatol,2007,46（2）:213-221.
[32] Singh V,Dhungana SP,Singh BR,et al. Midodrine in patients with cirrhosis and refractory or recurrent ascites: A randomized pilot study. J Hepatol,2012,56（2）:348-354.
[33] Tandon P,Tsuyuki RT,Mitchell L,et al. The effect of 1 month of therapy with midodrine,octreotide-lar and albumin in refractory ascites:A pilot study. Liver Int,2009,29（2）:169-174.
[34] Bari K,Minano C,Shea M,et al. The combination of octreotide and midodrine is not superior to albumin in preventing recurrence of ascites after large-volume paracentesis. Clin Gastroenterol Hepatol,2012,10（10）:1169-1175.
[35] Serste T,Melot C,Francoz C,et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology,2010,52（3）:1017-1022.
[36] Serste T,Francoz C,Durand F,et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites:A cross-over study. J Hepatol, 2011,55（4）:794-799.
[37] Krag A,Bendtsen F,Henriksen JH,et al. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut,2010,59（1）:105-110.
[38] Ge PS,Runyon BA. The changing role of beta-blocker therapy in patients with cirrhosis. J Hepatol,2014,60（3）: 643-653.
[39] Huonker M,Schumacher YO,Ochs A,et al. Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt. Gut,1999, 44（5）:743-748.
[40] Albillos A,Banares R,Gonzalez M,et al. A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. J Hepatol,2005,43（6）:990-996.
[41] Chen RP,Zhu Ge XJ,Huang ZM,et al. Prophylactic use of transjugular intrahepatic portosystemic shunt aids in the treatment of refractory ascites:Metaregression and trial sequential meta-analysis. J Clin Gastroenterol,2014,48（3）:290-299.
[42] Salerno F,Camma C,Enea M,et al. Transjugular intrahepatic portosystemic shunt for refractory ascites:A meta-analysis of individual patient data. Gastroenterology,2007,133（3）:825-834.
[43] Deltenre P,Mathurin P,Dharancy S,et al. Transjugular intrahepatic portosystemic shunt in refractory ascites:A meta-analysis. Liver Int,2005,25（2）:349-356.
[44] Lai KN, Pun CO,Leung JW. Study of hepatic venous wedge and intraperitoneal pressures in cirrhotic patients with refractory ascites treated by dialytic ultrafiltration. J Gastroen Hepatol,1989,4（4）:325-330.
[45] Martin P,DiMartini A,Feng S,et al. Evaluation for liver transplantation in adults: 2013 Practice Guidelines:by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology,2014,59（3）:1144-1165.

Optimal management of patients with liver cirrhosis and ascites

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	Bao Yingjun, Ren Weixin.. Interventional therapy for patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 768-769.
[3]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[4]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[5]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[6]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[7]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[8]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[9]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[10]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.
[11]	Ma Yaqiong, Li Zhilan, Xia Bing.. Early administration of enteral nutrition and microecological agents in patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2019, 22(6): 892-895.
[12]	Feng Wenguang, Jiang Wei, Song Guojun.. PPV-guided fluid therapy in patients with hepatolithiasis underwent partial hepatectomy [J]. Journal of Practical Hepatology, 2019, 22(6): 912-915.
[13]	Li Qiuxi, Jia Jianfeng, Huang Rui.. Clinical value of segmental pedicle hepatectomy and B-ultrasound-guided hepatectomy in the treatment of patients with hepatolithiasis [J]. Journal of Practical Hepatology, 2019, 22(6): 916-919.
[14]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[15]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.